右美托咪定联合不同阿片类药对老年患者单个椎体成形术镇痛效果的比较

注册号:

Registration number:

ChiCTR2500112302 

最近更新日期:

Date of Last Refreshed on:

2025-11-12 14:19:37 

注册时间:

Date of Registration:

2025-11-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

右美托咪定联合不同阿片类药对老年患者单个椎体成形术镇痛效果的比较

Public title:

Comparison of the analgesic effects of dexmedetomidine combined with different opioids for single-vertebra percutaneous vertebroplasty in elderly patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

右美托咪定联合不同阿片类药对老年患者单个椎体成形术镇痛效果的比较

Scientific title:

Comparison of the analgesic effects of dexmedetomidine combined with different opioids for single-vertebra percutaneous vertebroplasty in elderly patientsComparison of the analgesic effects of dexmedetomidine combined with different opioids for single-vertebra percutaneous vertebroplasty in elderly patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

苏娜英 

研究负责人:

毕聪杰;苏娜英 

Applicant:

Naying Su 

Study leader:

Congjie Bi;Naying Su 

申请注册联系人电话:

Applicant telephone:

+86 153 5480 9735

研究负责人电话:

Study leader's
telephone:

+86 135 0425 1513

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

0411-84412001

申请注册联系人电子邮件:

Applicant E-mail:

2645115142@qq.com

研究负责人电子邮件:

Study leader's E-mail:

congjie.bi@outlook.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

辽宁省大连市沙河口区西南路826号

研究负责人通讯地址:

辽宁省大连市沙河口区西南路826号

Applicant address:

826 Southwest Road, Shahekou District, Dalian, Liaoning

Study leader's address:

826 Southwest Road, Shahekou District, Dalian, Liaoning

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

大连理工大学附属中心医院(大连市中心医院)

Applicant's institution:

Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)

研究负责人所在单位:

大连理工大学附属中心医院(大连市中心医院)

Affiliation of the Leader:

Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

论审科研2025-224-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

大连理工大学附属中心医院伦理委员会

Name of the ethic committee:

Ethics Committee of Central Hospital of Dalian University of Technology

伦理委员会批准日期:

Date of approved by ethic committee:

2025-08-27 00:00:00

伦理委员会联系人:

方红

Contact Name of the ethic committee:

Hong Fang

伦理委员会联系地址:

辽宁省大连市沙河口区西南路826号

Contact Address of the ethic committee:

826 Southwest Road, Shahekou District, Dalian, Liaoning

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 411 8441 2001

伦理委员会联系人邮箱:

Contact email of the ethic committee:

zxyyllwyh@126.com

研究实施负责(组长)单位:

大连理工大学附属中心医院(大连市中心医院)

Primary sponsor:

Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)

研究实施负责(组长)单位地址:

辽宁省大连市沙河口区西南路826号

Primary sponsor's address:

826 Southwest Road, Shahekou District, Dalian, Liaoning

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁

市(区县):

大连

Country:

China

Province:

Liaoning

City:

Dalian

单位(医院):

大连理工大学附属中心医院(大连市中心医院)

具体地址:

辽宁省大连市沙河口区西南路826号

Institution
hospital:

Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)

Address:

826 Southwest Road, Shahekou District, Dalian, Liaoning

经费或物资来源:

Source(s) of funding:

None

研究疾病:

老年骨质疏松性脊柱压缩性骨折术中疼痛管理  

Target disease:

Intraoperative Pain Management for Osteoporotic Spinal Compression Fractures in the Elderly

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

比较右美托咪定联合不同阿片类药物对老年患者单个椎体成形术,采用局麻+MAC麻醉对患者术中镇痛的疗效。  

Objectives of Study:

Compare the efficacy of dexmedetomidine combined with different opioids on intraoperative analgesia in elderly patients undergoing single vertebroplasty under local anesthesia MAC.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.不能完成量表评估的患者;2.合并精神疾病史、慢性疼痛史、酒精或毒品滥用史;3.严重心、肺、肝、肾功能明显异常(转氨酶升高2倍及以上);4.对试验用药过敏;5.术前PaO2<60 mmHg或SpO2<92% ;6. 过去30天之内参与了另外的药物临床研究;

Exclusion criteria:

1. Patients unable to complete the scale assessment; 2. History of psychiatric disorders, chronic pain, or alcohol or drug abuse; 3. Severe dysfunction of the heart, lungs, liver, or kidneys (transaminase levels increased by 2 times or more); 4. Allergic to the study drug; 5. Preoperative PaO2 < 60 mmHg or SpO2 < 92%; 6. Participation in another drug clinical trial within the past 30 days.

研究实施时间:

Study execute time:

From 2025-11-01 00:00:00 To 2026-05-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-12-01 00:00:00 To 2026-05-01 00:00:00

干预措施:

Interventions:

组别:

右美托咪定组(D组)

样本量:

43

Group:

Dexmedetomidine group (Group D)

Sample size:

干预措施:

手术开始前5min静脉注射生理盐水5ml

干预措施代码:

Intervention:

Inject 5ml of saline intravenously 5 minutes before the surgery.

Intervention code:

组别:

右美托咪定+舒芬太尼组(DS组)

样本量:

43

Group:

Dexmedetomidine and Sufentanil Group (DS Group)

Sample size:

干预措施:

手术开始前5min静脉注射含有0.1ug/kg舒芬太尼5ml

干预措施代码:

Intervention:

Administer 5ml of sufentanil containing 0.1 μg/kg intravenously 5 minutes before surgery.

Intervention code:

组别:

右美托咪定+纳布啡组(DN组)

样本量:

43

Group:

Dexmedetomidine-Nalbuphine Group (DN Group)

Sample size:

干预措施:

手术开始前5min静脉注射含有0.1mg/kg纳布啡5ml

干预措施代码:

Intervention:

Administer 5ml of intravenous nalbuphine at 0.1mg/kg 5 minutes before the surgery.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁 

市(区县):

大连 

Country:

China

Province:

Liaoning

City:

Dalian

单位(医院):

大连理工大学附属中心医院(大连市中心医院) 

单位级别:

三甲 

Institution
hospital:

Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疼痛VAS评分

指标类型:

主要指标

Outcome:

VAS score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

收缩压

指标类型:

次要指标

Outcome:

Systolic Blood Pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

舒张压

指标类型:

次要指标

Outcome:

Diastolic Blood Pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

平均动脉压

指标类型:

次要指标

Outcome:

Mean arterial pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

Heart rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脉搏血氧饱和度

指标类型:

次要指标

Outcome:

Pulse oxygen saturation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Ramsay镇静评分

指标类型:

次要指标

Outcome:

Ramsay Sedation Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血管活性药物使用剂量

指标类型:

次要指标

Outcome:

Dosage of vasoactive drugs

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血管活性药物使用次数

指标类型:

次要指标

Outcome:

Number of times vasoactive drugs are used

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

3D-CAM量表

指标类型:

次要指标

Outcome:

3D-CAM Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者术后24h术后恢复质量评分(Qor-15)

指标类型:

次要指标

Outcome:

Qor-15

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者疼痛满意度

指标类型:

次要指标

Outcome:

Patient pain satisfaction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术者疼痛满意度

指标类型:

次要指标

Outcome:

Postoperative Pain Satisfaction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中重度疼痛发生率

指标类型:

次要指标

Outcome:

Incidence of moderate to severe pain

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应

指标类型:

次要指标

Outcome:

Adverse reaction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究人员使用SPSS 25.0软件生成随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Researchers use SPSS 25.0software to generate random sequences

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

患者、外科医生、麻醉科医护人员、术后护理人员以及负责数据收集和结局评估的研究人员均对分组情况不知情。

Blinding:

Patients, surgeons, anesthesia staff, postoperative care personnel, and researchers responsible for data collection and outcome evaluation were all unaware of the group assignments.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

1、病例记录表 2、电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1. CRF 2. an electronic data capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-11-12 14:19:28